Chronic progressive diseases, particularly those of the immune system impact people – physically, mentally and socially. We put patient needs at the center of everything we do, from our dedication to providing high quality products to our disease awareness-raising efforts.

The MS treatment journey can be challenging for people living with MS, and we aim to make the experience as stress-free as possible for them. That is why we develop options aimed at lessening treatment burden, improving adherence and making administration more convenient. In order to do this successfully, we continue to expand our understanding of the overall challenges and needs of patients as well as foster debate amongst the MS community in an effort to improve care outcomes

повеќе информации

MULTIPLE SCLEROSIS
ТРЕТМАН
ФУСНОТИ И РЕФЕРЕНЦИ

ФУСНОТИ И РЕФЕРЕНЦИ

*MAVENCLAD‭‭ is indicated for the treatment of adult patients with highly active RMS as defined by clinical or imaging feature‭s‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬‬ 

**There are currently no head-to-head trials. From publicly available information, accurate at date of creation – September 2018 

†Disease control refers to 75.6% of patients who remained relapse-free without further treatment in Years 3 and 43 

††See Rebif prescribing information for more details. 

 

  1. MAVENCLAD® SmPC, 2017.
  2. Giovannoni G et al. N Engl J Med 2010; 362:416–426. 
  3. Giovannoni G et al. EAN 2017; [P0542].
  4. Giovannoni G et al. Mult Scler 2017; doi: 10.1177/1352458517727603.
  5. Rebif® EU Summary of Product Characteristics, December 2017. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000136/WC500048681.pdf [Accessed 25 April 2018].
  6. De Stefano N et al. J Neurol Sci 2012; 312:97–101.
  7. Kappos L et al. J Neurol Neurosurg Psychiatry 2015; 86:1202–1207

DMD – disease modifying drug

MRI – magnetic resonance imaging

MS – multiple sclerosis

RMS – relapsing multiple sclerosis